NCT02853331 2026-02-02KEYNOTE-426Merck Sharp & Dohme LLCPhase 3 Completed861 enrolled 24 charts 2 FDA
NCT00920816 2022-05-06Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell CancerPfizerPhase 3 Completed492 enrolled 17 charts
NCT00678392 2019-01-09Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell CancerPfizerPhase 3 Completed723 enrolled 15 charts
NCT00471146 2012-07-16Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.PfizerPhase 3 Completed630 enrolled 13 charts